{"classes":[{"categories":[{"measurements":[{"comment":"Not available. Upper limit not reached due to insufficient number of events at later stages of follow-up.","groupId":"OG000","lowerLimit":"18.3","upperLimit":"NA","value":"33.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Approximately 4.5 years after first participant enrolled"},{"categories":[{"measurements":[{"comment":"Not available. Upper limit not reached due to insufficient number of events at later stages of follow-up.","groupId":"OG000","lowerLimit":"18.3","upperLimit":"NA","value":"33.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"Approximately 6.5 years after first participant enrolled"}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"description":"OS was defined as the time from the date of the first administration of any study drug until death from any cause (documented by the date of death).","dispersionType":"95% Confidence Interval","groups":[{"description":"MOR00208:\n\nMOR00208 was administered via IV infusion at a dose of 12 mg/kg. For the first three cycles (Cycles 1 to 3) of the study each cycle consisted of a MOR00208 infusion on Day 1, Day 8, Day 15 and Day 22 of the cycle.\n\nAdditionally, a loading dose was administered on Day 4 of Cycle 1. Thereafter MOR00208 was administered on a bi-weekly (every 14 days) basis with infusions on Day 1 and Day 15 of each 28-day cycle.\n\nLEN:\n\nParticipants self-administered a starting dose of 25 mg oral LEN daily on Days 1-21 of each cycle, for up to 12 cycles in total. LEN dose could be modified in a de-escalating fashion or discontinued based upon clinical and laboratory findings.\n\nOn days when both study drugs were given together, LEN was administered prior to MOR00208.","id":"OG000","title":"Tafasitamab (MOR00208) + Lenalidomide (LEN)"}],"paramType":"MEDIAN","populationDescription":"FAS: The FAS includes all participants who received at least one dose of MOR00208 and one dose of LEN. This means that both study drugs must have been applied at least once. Inclusive of participants with available data.","reportingStatus":"POSTED","timeFrame":"Approximately 4.5 years after first participant enrolled; Approximately 6.5 years after first participant enrolled","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}